uniQure (NASDAQ:QURE) Stock Jumps 5.6% – What’s Next?

uniQure N.V. (NASDAQ:QURE) was up 5.6% during trading on Thursday. The company traded as high as $25.70 and last traded at $25.9570. 646,975 shares traded hands during trading, a decline of 73% from the average daily volume of 2,401,587 shares. The stock had previously closed at $24.58.

Analyst Ratings Changes

Several equities analysts recently issued reports on QURE shares. Wells Fargo & Company reissued an “overweight” rating and set a $75.00 price objective on shares of uniQure in a research note on Tuesday, September 29th. The Goldman Sachs Group lowered their target price on shares of uniQure from $46.00 to $31.00 and set a “neutral” rating for the company in a research note on Wednesday, September 30th. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Weiss Ratings upgraded uniQure from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, September 21st. Finally, UBS Group initiated coverage on uniQure in a report on Thursday, October 15th. They set a “buy” rating and a $48.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, uniQure has an average rating of “Moderate Buy” and a consensus target price of $56.83.

uniQure Price Performance

The company’s 50 day moving average price is $30.35 and its 200-day moving average price is $29.68. The company has a market capitalization of $1.81 billion, a PE ratio of -7.34 and a beta of 1.14. The company has a current ratio of 11.52, a quick ratio of 11.52 and a debt-to-equity ratio of 0.17.

uniQure (NASDAQ:QURE) last issued its earnings results on Wednesday, November 4th. The biotechnology company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.04. uniQure had a negative return on equity of 96.34% and a negative net margin of 1,154.84%. The business had revenue of $5.20 million for the quarter, compared to analyst estimates of $6.17 million. On average, sell-side analysts forecast that uniQure N.V. will post -3.83 earnings per share for the current fiscal year.

Hedge Funds Weigh In On uniQure

Several hedge funds and other institutional investors have recently modified their holdings of QURE. Orbimed Advisors LLC grew its holdings in shares of uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after purchasing an additional 1,398,749 shares during the period. Two Seas Capital LP purchased a new position in uniQure in the third quarter valued at approximately $31,988,000. Siren L.L.C. purchased a new position in uniQure in the first quarter valued at approximately $16,350,000. Assenagon Asset Management S.A. lifted its position in uniQure by 249.9% during the second quarter. Assenagon Asset Management S.A. now owns 513,530 shares of the biotechnology company’s stock valued at $23,653,000 after buying an additional 366,781 shares in the last quarter. Finally, Kalehua Capital Management LLC acquired a new position in uniQure during the first quarter valued at approximately $4,760,000. 78.83% of the stock is owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. is a biotechnology company that develops gene therapies for serious genetic and other diseases. The company uses adeno-associated virus (AAV) vectors to deliver genetic material to patients’ cells, with research and development operations in the United States and the Netherlands. Its programs have targeted conditions including Huntington’s disease, epilepsy and hemophilia B. uniQure developed the gene therapy now known as Hemgenix for hemophilia B; it is commercialized by CSL Behring under a partnership.